The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark
Conclusion: Oral semaglutide+metformin seems not cost-effective versus empagliflozin+metformin in patients uncontrolled on metformin in Denmark.PMID:34841893 | DOI:10.2217/cer-2021-0169
Source: Journal of Comparative Effectiveness Research - Category: General Medicine Authors: Lars H Ehlers Mark Lamotte Mafalda C Ramos Susanne Sandgaard Pia Holmgaard Evan C Frary Niels Ejskjaer Source Type: research
More News: Denmark Health | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | General Medicine | Jardiance | Metformin | Study